A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Banerji, U., Dean, E. J., Perez-Fidalgo, J. A., Batist, G., Bedard, P. L., You, B., Westin, S. N., Kabos, P., Garrett, M. D., Tall, M., Ambrose, H., Barrett, J. C., Carr, T. H., Cheung, S. Y. A., Corcoran, C., Cullberg, M., Davies, B. R., de Bruin, E. C., Elvin, P., Foxley, A., Lawrence, P., Lindemann, J. P. O., Maudsley, R., Pass, M., Rowlands, V., Rugman, P., Schiavon, G., Yates, J., Schellens, J. H. M.
The American Association for Cancer Research (AACR)
Published 2018